Instrument Inactif

Autres langues Aerpio Pharmaceuticals

Actions

ARPO

US00810B1052

Autres langues

04/01/22	Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference
23/11/21	Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
15/11/21	UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)
19/10/21	Aerpio Pharmaceuticals : Aadi Bioscience to Participate in H.C. Wainwright’s 2nd Annual Precision Oncology Conference 2021
27/08/21	Aadi Bioscience Completes Merger With Aerpio Pharmaceuticals; Shares Decline on Nasdaq Debut
27/08/21	AADI BIOSCIENCE, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Amendment or Waiver to Code of Ethics, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits (form 8-K)
27/08/21	Aerpio Pharmaceuticals, Inc.(NasdaqCM:ARPO) dropped from NASDAQ Composite Index
27/08/21	Aerpio Pharmaceuticals : Aadi Bioscience Corporate Overview
26/08/21	Aadi Bioscience, Inc. completed the acquisition of Aerpio Pharmaceuticals, Inc. in a reverse merger transaction.
23/08/21	Aerpio Pharmaceuticals : ASSET PURCHASE AGREEMENT (Form 8-K)
23/08/21	AERPIO PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
18/08/21	Aerpio Pharmaceuticals : Submission of Matters to a Vote of Security Holders (Form 8-K)
18/08/21	AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
11/08/21	AERPIO PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
11/08/21	Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update (Form 8-K)
11/08/21	Aerpio Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
11/08/21	Aerpio Pharmaceuticals : Reports Second Quarter 2021 Financial Results and Provides Business Update
26/07/21	Aerpio Pharmaceuticals : Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa (Form 8-K)
26/07/21	AERPIO PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
07/06/21	Aerpio Pharmaceuticals : Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
04/06/21	Aerpio Pharmaceuticals : Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting (Form 8-K)
04/06/21	AERPIO PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
04/06/21	Aerpio Provides Second Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting
21/05/21	AERPIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerpio Pharmaceuticals, Inc. - ARPO
20/05/21	Aerpio Pharmaceuticals : Provides Update on Aadi Bioscience Presentation at the ASCO 2021 Virtual Meeting (Form 8-K)